Zynerba updates on its two clinical CBD studies





Zynerba Pharmaceuticals (NASDAQ:ZYNE) CEO Armando Anido caught up with Proactive Investors at the BIO CEO & Investor Conference in New York.

Be the first to comment

Leave a Reply

Your email address will not be published.


*